The global dystrophin market is expected to experience substantial growth, increasing from USD 1.30 Billion in 2020 to reach USD 28.20 Billion by 2028. This growth is projected to occur at a compound annual growth rate (CAGR) of 47.00% during the forecast period of 2019-2026. Several factors contribute to this growth, including a high incidence of Duchenne muscular dystrophy (DMD) worldwide, a favorable funding environment for DMD research and development, significant healthcare expenditure potential in developed nations, and the availability of medical reimbursement in various regions globally.
https://www.reportsanddata.com..../report-detail/dystr